Table 2. Analysis of genotype frequencies in NOS2 gene polymorphisms between control and BPH subjects.

SNP (locus)	Genotype	Group		Model	OR (95% CI)	P-value
		Control	BPH
		n = 205 (%)	n = 229 (%)
rs2779248	T/T	148 (72.2)	182 (79.5)	Codominant	0.79 (0.53–1.17)	0.240
Promoter	T/C	55 (26.8)	40 (17.5)	Dominant	0.66 (0.42–1.04)	0.074
−278	C/C	2 (1.0)	7 (3.1)	Recessive	2.93 (0.59–14.61)	0.160
rs10459953	G/G	69 (33.7)	66 (28.8)	Codominant	1.16 (0.88–1.52)	0.290
5′UTR	C/G	94 (45.9)	109 (47.6)	Dominant	1.23 (0.81–1.87)	0.340
	C/C	42 (20.5)	54 (23.6)	Recessive	1.21 (0.75–1.94)	0.430
rs2297518	G/G	164 (80.0)	168 (73.4)	Codominant	1.54 (0.99–2.39)	0.053
Missense	A/G	41 (20.0)	56 (24.4)	Dominant	1.47 (0.92–2.34)	0.100
Ser608Leu	A/A	0 (0.0)	5 (2.2)	Recessive		0.040*

Abbreviations: 5′UTR, 5′-untranslated region; BPH, benign prostatic hyperplasia; CI, confidence interval; n, number of subjects; NOS2, nitric oxide synthase 2; OR, odds ratio; SNP, single nucleotide polymorphism.

Note: P-values were obtained from logistic regression analyses with the codominant, dominant and recessive models without Bonferroni correction.

^*P-value was tested using Fisher's exact test.